Idiopathic Pulmonary Fibrosis

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
Luke M Kraven, Adam R Taylor, Philip L Molyneaux, Toby M Maher, John E McDonough, Marco Mura, Ivana V Yang, David A Schwartz, Yong Huang, Imre Noth, Shwu Fan Ma, Astrid J Yeo, William A Fahy, R Gisli Jenkins, Louise V Wain

Thorax May 2022, thoraxjnl-2021-218563; DOI: 10.1136/thoraxjnl-2021-218563
Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study
Sabina Anna Guler, Seo Am Hur, Michael K Stickland, Patrick Brun, Luc Bovet, Anne E Holland, Janet Bondarenko, Nathan Hambly, Joshua Wald, Nima Makhdami, Michael Kreuter, Rainer Gloeckl, Inga Jarosch, Benjamin Tan, Kerri A Johannson, S Ainslie McBride, Kaissa De Boer, Jacqueline S Sandoz, Kelly Sun, Deborah Assayag, Surya P Bhatt, Julie Morisset, Vincent Ferraro, Chris Garvey, Pat G Camp, Christopher J Ryerson

Thorax Jun 2022, 77 (6) 589-595; DOI: 10.1136/thoraxjnl-2021-217361
Impact of smoking on the development of idiopathic pulmonary fibrosis: results from a nationwide population-based cohort study
Won Bae, Chang-Hoon Lee, Jinwoo Lee, Young Whan Kim, Kyungdo Han, Sun Mi Choi

Thorax May 2022, 77 (5) 470-476; DOI: 10.1136/thoraxjnl-2020-215386
Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis
Hyogo Naoi, Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Yusuke Inoue, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda

Thorax Mar 2022, thoraxjnl-2021-218281; DOI: 10.1136/thoraxjnl-2021-218281
Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis
Abhimanyu Chandel, Jean Pastre, Solène Valery, Christopher S King, Steven D Nathan

Thorax Mar 2022, thoraxjnl-2021-218440; DOI: 10.1136/thoraxjnl-2021-218440
CHK yourself, before you wreck yourself: targeting the DNA damage response in secondary pulmonary hypertension
Andrew Bryant, Vinicio de Jesus Perez

Thorax Mar 2022, 77 (3) 218-219; DOI: 10.1136/thoraxjnl-2021-217882
Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension
Wen-Hui Wu, Sébastien Bonnet, Tsukasa Shimauchi, Victoria Toro, Yann Grobs, Charlotte Romanet, Alice Bourgeois, Geraldine Vitry, Junichi Omura, Eve Tremblay, Valerie Nadeau, Mark Orcholski, Sandra Breuils-Bonnet, Sandra Martineau, Pasquale Ferraro, Francois Potus, Roxane Paulin, Steeve Provencher, Olivier Boucherat

Thorax Mar 2022, 77 (3) 247-258; DOI: 10.1136/thoraxjnl-2021-217377
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
Tyler Pitre, Jasmine Mah, Wryan Helmeczi, Muhammad Faran Khalid, Sonya Cui, Melanie Zhang, Renata Husnudinov, Johnny Su, Laura Banfield, Brent Guy, Jade Coyne, Ciaran Scallan, Martin RJ Kolb, Aaron Jones, Dena Zeraatkar

Thorax Feb 2022, thoraxjnl-2021-217976; DOI: 10.1136/thoraxjnl-2021-217976
Association of circulating cell-free double-stranded DNA and metabolic derangements in idiopathic pulmonary fibrosis
William Whalen, Mustafa Buyukozkan, Bethany Moore, Jong-Seok Moon, Charles S Dela Cruz, Fernando J Martinez, Augustine M K Choi, Jan Krumsiek, Heather Stout-Delgado, Soo Jung Cho

Thorax Feb 2022, 77 (2) 186-190; DOI: 10.1136/thoraxjnl-2021-217315
Circulating cell-free double-stranded DNA and metabolic derangements in idiopathic pulmonary fibrosis: a new association
Yuben P Moodley

Thorax Feb 2022, 77 (2) 114; DOI: 10.1136/thoraxjnl-2021-218192

Main menu

Idiopathic Pulmonary Fibrosis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Idiopathic Pulmonary Fibrosis

Pages